142
Views
16
CrossRef citations to date
0
Altmetric
Brief Report

Surveillance study of the susceptibility of Haemophilus influenzae to various antibacterial agents in Europe and Canada

, , , &
Pages 2853-2861 | Accepted 01 Aug 2008, Published online: 28 Aug 2008
 

ABSTRACT

Background: Haemophilus influenzae is a major respiratory tract pathogen that is becoming increasingly resistant to β-lactam antibiotics.

Materials and methods: Using a microdilution method performed to Clinical and Laboratory Standards Institute (CLSI) guidelines, we determined the minimal inhibitory concentrations (MICs) of various antibacterial agents against 536 isolates of H. influenzae. The isolates were obtained from patients with respiratory tract infections being treated in 18 European and two Canadian centres between 2006 and 2007.

Results: Levofloxacin, moxifloxacin, cefixime and cefpodoxime with MIC90 values of ≤ 0.03, ≤ 0.03, 0.03 and 0.06 μg/mL, respectively, were the four most active agents tested. Overall, amoxicillin resistance was observed in 25.0% of the strains, but was generally reversed with the addition of clavulanic acid. In 73 strains (13.6%) resistance was due to β-lactamase (BL) production while the remainder (n = 61; 11.4%) were BL-negative, amoxicillin-resistant (BLNAR) strains. Comparison of penicillin binding protein 3B sequences in BLNAR isolates revealed that only mutations at amino acids 502 (alanine [Ala] → threonine [Thr]/valine [Val]) and 526 (asparagine [Asn] → lysine [Lys]) were significantly associated with amoxicillin resistance among European H. influenzae isolates ( p < 0.0001 for both).

Conclusions: This surveillance study highlights an increased prevalence of amoxicillin-resistant strains of H. influenzae compared with a previous study that we performed in 2004/2005. The third-generation cephalosporins cefixime and cefpodoxime, as well as amoxicillin plus clavulanic acid, continue to be very active against both BL-positive and BLNAR strains of H. influenzae, and thus remain useful treatment options for patients with respiratory tract infections.

Acknowledgements

Declaration of interest: This study was financially supported by Astellas Pharma Inc. The authors would like to thank Steve Clissold PhD, Content Ed Net for editorial assistance (with funding provided by Astellas).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.